Structure Therapeutics Inc.

The Company invests its cash, cash equivalents and short-term investments in money market funds, corporate debt securities, U.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

government agency bonds 34,647 34,647 24,941 24,941 Corporate debt securities 396,743 396,743 236,241 236,241 Total fair value of financial assets $ 905,662 $ 431,390 $ $ 1,337,052 $ 1,180,481 $ 261,182 $ $ 1,441,663 JUNE 30, DECEMBER 31, 2026 2025 AMORTIZED GROSS UNREALIZED FAIR AMORTIZED GROSS UNREALIZED FAIR COST LOSSES GAINS VALUE COST LOSSES GAINS VALUE Money market funds $ 267,032 $ $ $ 267,032 $ 795,089 $ $ $ 795,089 U.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

government agency bonds 34,802 ( 155 ) 34,647 24,922 19 24,941 Corporate debt securities 397,509 ( 777 ) 11 396,743 236,027 ( 16 ) 230 236,241 Total fair value of financial assets $ 1,340,497 $ ( 3,501 ) $ 56 $ 1,337,052 $ 1,440,609 $ ( 17 ) $ 1,071 $ 1,441,663 As of June 30, 2026 and December 31, 2025, the Company did not have any liabilities measured at fair value on a recurring basis.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

Ordinary shareholders are entitled to dividends if and when declared by the Company s board of directors.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

As of June 30, 2026 and December 31, 2025, no dividends on ordinary shares had been declared by the board of directors.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

The Pre-Funded Warrants are classified as a component of permanent equity within the Company's condensed consolidated balance sheets as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of ordinary shares upon exercise.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

(NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.

SEC original ↗Structure Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

· Phase 2 study to assess a maintenance switching strategy from an approved injectable GLP-1 receptor agonist to aleniglipron – Specifically, this maintenance switching study will evaluate the transition from an approved injectable GLP-1 receptor agonist to once-daily oral aleniglipron for weight loss maintenance.

SEC original ↗Structure Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

About Structure Therapeutics Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs.

SEC original ↗Structure Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

The forward-looking statements in this Quarterly Report are only predictions and are based largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

You should carefully consider these risks and uncertainties when investing in our securities.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

Legal Proceedings 36 Item 1A.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of known and unknown risks, uncertainties, and assumptions, including those described under Part I.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon these forward-looking statements as predictions of future events.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

RISK FACTORS SUMMARY Our business is subject to numerous risks and uncertainties, including those described in Part II.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026

You should carefully consider these risks and uncertainties when investing in our securities.

SEC original ↗Structure Therapeutics Inc. — 10-Q Quarterly report10-QAug 6, 2026